Molecular and cytogenetic remission in a case of subtype M4E acute myelogenous leukemia with minimal monochemotherapy: high sensitivity or spontaneous remission?

Martelli, Maria Paola; Latagliata, Roberto; Spadea, Antonio; Avvisati, Giuseppe; Mancini, Marco; Romano, Atelda; Luzi, G.; Petti, Maria Concetta

doi:10.1034/j.1600-0609.2000.9c220.x

Cited by 7 publications

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As was previously noted for the HLA-A2 -presented, melanomaassociated MART-1 [27][28][29][30][31][32][33][34][35] epitope (35), we hypothesized that the high degree of normal donor response against the MAGE-A6 Th peptides might be due to the cross-reactivity of T cells initially primed in vivo against highly homologous peptides within environmentally encountered proteins. After performing a homology search of the GenBank database, we selected the MPHF2 216-229 and CHP [42][43][44][45][46][47][48][49][50][51][52][53][54][55] peptides as two likely candidate homologues of the MAGE-A6 172-187 and MAGE-A6 280-302 peptides, respectively. The MPHF2 peptide derives from M. penetrans HF-2, a ubiquitous species of Mycoplasmataceae, which infects the urogenital and respiratory tracts of humans.…”

Section: Discussionmentioning

confidence: 99%

A Mycoplasma Peptide Elicits Heteroclitic CD4+ T Cell Responses against Tumor Antigen MAGE-A6

Vujanović

Mandić²,

Olson³

et al. 2007

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Although T-helper (Th) epitopes have been previously reported for many tumor antigens, including MAGE-A6, the relevant HLA-DR alleles that present these peptides are expressed by only a minority of patients. The identification of tumor antigenic epitopes presented promiscuously by many HLA-DR alleles would extend the clinical utility of these peptides in vaccines and for the immunomonitoring of cancer patients. Experimental Design: A neural network algorithm and in vitro sensitization assays were employed to screen candidate peptides for their immunogenicity. Results: The MAGE-A6 14 0 -170 , MAGE-A6 172-187 , and MAGE-A6 280-302 epitopes were recognized by CD4 + T cells isolated from the majority of normal donors and melanoma patients evaluated. Peptide-specific CD4 + T cells also recognized autologous antigen-presenting cell pulsed with recombinant MAGE-A6 (rMAGE) protein, supporting the natural processing and MHC presentation of these epitopes. Given the strong primary in vitro sensitization of normal donor CD4 + T cells by the MAGEA6 172-187 epitope, suggestive of potential cross-reactivity against an environmental stimulus, we identified a highly homologous peptide within the Mycoplasma penetrans HF-2 permease (MPHF2) protein. MPHF2 peptide^primed CD4 + Tcells cross-reacted against autologous APC pulsed with the MAGE-A6 172-187 peptide or rMAGE protein and recognized HLA-matched MAGE-A6 + melanoma cell lines. These responses seemed heteroclitic in nature because the functional avidity of MPHF2 peptide-primed CD4 + Tcells for the MAGE-A6 172-187 peptide was f1,000 times greater than that of CD4 + T cells primed with the corresponding MAGE-A6 peptide. Conclusions: We believe that these novel ''promiscuous'' MAGE-A6/MPHF2 Th epitopes may prove clinically useful in the treatment and/or monitoring of a high proportion of cancer patients.

show abstract

Section: Discussionmentioning

confidence: 99%

A Mycoplasma Peptide Elicits Heteroclitic CD4+ T Cell Responses against Tumor Antigen MAGE-A6

Vujanović

Mandić²,

Olson³

et al. 2007

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…More than 100 cases of spontaneous remission (SR) interrupting the invariably progressive course of untreated acute myeloblastic leukemia (AML) have been reported so far. Of these, 32 SRs have been published since 1980 and nine (1–9) of these also had a cytogenetic SR (Table 1). Only three SRs occurred in an AML secondary to a myelodysplastic syndrome (MDS) (10, 11).…”

Section: Cases Of Spontaneous Remission In Course Of Acute Myeloblastmentioning

confidence: 99%

“…Until now the various SRs described during the course of AML remain unexplained. Cytogenetic SRs, which surprisingly prevail in cases characterized by t(8;21) (5, 7, 9), occurring in the absence of any chemotherapy, are particularly attractive, because these rare events (1–9) point to the spontaneous restoration of normal hemopoiesis. As it has been shown in SRs occurring in chronic lymphocytic leukemia (15), it would be interesting to evaluate the level of the minimal residual disease by immunophenotypic and molecular studies just in these patients.…”

Section: Cases Of Spontaneous Remission In Course Of Acute Myeloblastmentioning

confidence: 99%

Cytogenetic and hematological spontaneous remission in a case of acute myelogenous leukemia

Fozza¹,

Bellizzi²,

Bonfigli³

et al. 2004

European J of Haematology

View full text Add to dashboard Cite

Several cases of spontaneous remission (SR) interrupting the invariably progressive course of untreated acute myeloblastic leukemia (AML) have been reported so far. We shall add to this series the hematological and cytogenetic SR occurring in a 72-yr-old man affected by AML following myelodysplastic syndrome. At diagnosis cytogenetic analysis showed the 48, xy, del (6) (p22-pter), +13, +14 karyotype. Owing to a lobar pneumonia, the chemotherapy was deferred and a broad spectrum antibiotic therapy was established. Supportive care included red cells and platelet transfusions and low-dose corticosteroid. Two months later, after the pneumonia had completely disappeared, a complete remission, lasting about 5 months, was documented on bone marrow morphological and cytogenetical examination, although some degree of myeloid dysplasia persisted. Possible mechanisms of the various SRs described during the course of AML are discussed with a review of the literature.

show abstract

Remission of Acute Myeloblastic Leukemia After Severe Pneumonia Treated With High-Dose Methylprednisolone

2001

View full text Add to dashboard Cite

We report a case of acute myeloblastic leukemia (AML)-M2 (by French-American-British classification) with t(8;21) (q22:q22) that was complicated with severe pneumonia. The patient tested positive by fluorescence in situ hybridization (FISH) for AML1 splitting and positive by reverse transcriptase polymerase chain reaction (RT-PCR) for chimeric AML1/MTG8 messenger RNA (mRNA), which indicated splitting of the MTG8 gene on chromosome 8 (q22) and the AMLI gene on chromosome 22 (q22). High-dose methylprednisolone was administered, and the leukemic cells disappeared without chemotherapy, although dysplastic hematopoietic cells were observed transiently after the first therapy. After the disappearance of leukemic cells, FISH for AML1 splitting was negative, and real-time PCR results for quantitative chimeric AML1/ MTG8 mRNA were less than the detectable level, however, RT-PCR results for AML1/MTG8 mRNA remained positive. These findings suggest that the patient acquired morphological, cytogenetic. and possibly molecular genetic remission by the synergistic effects of severe infection and high-dose methylprednisolone.

show abstract

Molecular and cytogenetic remission in a case of subtype M4E acute myelogenous leukemia with minimal monochemotherapy: high sensitivity or spontaneous remission?

Cited by 7 publications

References 3 publications

A Mycoplasma Peptide Elicits Heteroclitic CD4+ T Cell Responses against Tumor Antigen MAGE-A6

A Mycoplasma Peptide Elicits Heteroclitic CD4+ T Cell Responses against Tumor Antigen MAGE-A6

Cytogenetic and hematological spontaneous remission in a case of acute myelogenous leukemia

Remission of Acute Myeloblastic Leukemia After Severe Pneumonia Treated With High-Dose Methylprednisolone

Contact Info

Product

Resources

About